Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1317922rdf:typepubmed:Citationlld:pubmed
pubmed-article:1317922lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:1317922lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:1317922lifeskim:mentionsumls-concept:C1553038lld:lifeskim
pubmed-article:1317922lifeskim:mentionsumls-concept:C0244485lld:lifeskim
pubmed-article:1317922pubmed:issue11lld:pubmed
pubmed-article:1317922pubmed:dateCreated1992-7-8lld:pubmed
pubmed-article:1317922pubmed:abstractTextThis paper describes the synthesis of some conformationally restricted 4-phenylpiperidine analogues and their affinities for the guinea pig cerebellum sigma recognition site ([3H]-DTG) and the rat striatum dopamine D2 receptor ([3H]-(-)-sulpiride) in order to develop potent selective sigma ligands as tools in the investigation of this site in psychosis. It was found that both hexa- and octahydrobenz[f]isoquinolines with lipophilic N-substituents had high affinities for the sigma site. Notably, trans-3-cyclohexyl-1,2,3,4,4a,5,6,10b-octahydrobenz[f]isoquinoline (26) had an affinity of 0.25 nM making it the highest affinity sigma ligand reported to date. Moreover, it is at least 10,000-fold selective over the D2 receptor and could prove to be a valuable tool in the study of sigma sites. Other analogues such as 1H-indeno[2,1-c]pyridines and 1H-benzo[3,4]cyclohepta[1,2-c]pyridines also displayed high sigma site affinity.lld:pubmed
pubmed-article:1317922pubmed:languageenglld:pubmed
pubmed-article:1317922pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1317922pubmed:citationSubsetIMlld:pubmed
pubmed-article:1317922pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1317922pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1317922pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1317922pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1317922pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1317922pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1317922pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1317922pubmed:statusMEDLINElld:pubmed
pubmed-article:1317922pubmed:monthMaylld:pubmed
pubmed-article:1317922pubmed:issn0022-2623lld:pubmed
pubmed-article:1317922pubmed:authorpubmed-author:BakerRRlld:pubmed
pubmed-article:1317922pubmed:authorpubmed-author:MiddlemissD...lld:pubmed
pubmed-article:1317922pubmed:authorpubmed-author:BillingtonD...lld:pubmed
pubmed-article:1317922pubmed:authorpubmed-author:NobleA JAJlld:pubmed
pubmed-article:1317922pubmed:authorpubmed-author:RussellM GMGlld:pubmed
pubmed-article:1317922pubmed:authorpubmed-author:KnightA KAKlld:pubmed
pubmed-article:1317922pubmed:issnTypePrintlld:pubmed
pubmed-article:1317922pubmed:day29lld:pubmed
pubmed-article:1317922pubmed:volume35lld:pubmed
pubmed-article:1317922pubmed:ownerNLMlld:pubmed
pubmed-article:1317922pubmed:authorsCompleteYlld:pubmed
pubmed-article:1317922pubmed:pagination2025-33lld:pubmed
pubmed-article:1317922pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:meshHeadingpubmed-meshheading:1317922-...lld:pubmed
pubmed-article:1317922pubmed:year1992lld:pubmed
pubmed-article:1317922pubmed:articleTitleBenz[f]isoquinoline analogues as high-affinity sigma ligands.lld:pubmed
pubmed-article:1317922pubmed:affiliationChemistry Department, Merck Sharp and Dohme Research Laboratories, Harlow, Essex, U.K.lld:pubmed
pubmed-article:1317922pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:1317922lld:chembl